Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinlianqingre Effervescent Tablets (JET) is a traditional Chinese medicine (TCM) formulation developed by the China Academy of Chinese Medical Sciences for the treatment of uncomplicated or mild hand, foot, and mouth disease (HFMD) in children. Classified as a 'heat-clearing and detoxifying' remedy, it is used to reduce fever resolution time and accelerate the healing of skin rashes and oral ulcers. The formulation is an effervescent tablet designed for pediatric ease of use and is typically administered in combination with conventional supportive therapies. It is recommended by the Ministry of Health of China as a control measure for mild HFMD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinlianqingre Effervescent Tablets.